Literature DB >> 8581558

Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

V Jackson-Lewis1, M Jakowec, R E Burke, S Przedborski.   

Abstract

Mechanisms responsible for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopamine (DA) neuronal death remain unknown and in mice it is even unclear whether neuronal death does occur. In vitro studies suggest that 1-methyl-4-phenylpyridinium ion (MPP+), the active metabolite of MPTP, kills neurons by apoptosis. Herein, we investigated whether MPTP induces DA neuronal death in vivo in mice and whether the mechanism is that of apoptosis. C57/bl Mice received different doses of MPTP administered in four intraperitoneal injections every 2 hours and were sacrificed at different time points for analyses of tyrosine hydroxylase (TH) immunohistochemistry, silver staining, and Nissl staining within the mesencephalon. We found that MPTP induces neuronal destruction in the substantia nigra pars compacta (SNpc) and the ventral tegmental area (VTA). The active phase of degeneration began at 12 h postinjection and continued up to 4 days. During this period, there was a greater decrease in TH-defined neurons than in Nissl-stained neurons suggesting that MPTP can cause a loss in TH without necessarily destroying the neuron. Thereafter, neuronal counts by both techniques equalized and there was no further loss of DA neurons. Dying neurons showed shrunken eosinophilic cytoplasm and shrunken darkly stained nuclei. Double staining revealed degenerating neurons solely among TH positive neurons of SNpc and VTA. At no time point and at no dose of MPTP was apoptosis observed. In addition, in situ labelling revealed no evidence of DNA fragmentation. This study demonstrates that the MPTP mouse model replicates several key features of neurodegeneration of DA neurons in PD and provides no in vivo evidence that, using this specific paradigm of injection, MPTP kills DA neurons by apoptosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581558     DOI: 10.1016/1055-8330(95)90015-2

Source DB:  PubMed          Journal:  Neurodegeneration        ISSN: 1055-8330


  166 in total

1.  Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting.

Authors:  D D Song; S N Haber
Journal:  J Neurosci       Date:  2000-07-01       Impact factor: 6.167

2.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  Du-Chu Wu; Peter Teismann; Kim Tieu; Miquel Vila; Vernice Jackson-Lewis; Harry Ischiropoulos; Serge Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

4.  MPTP-induced apoptosis in the retina of goldfish.

Authors:  L Villani; A Beraudi; A Giuliani; A Poli
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

Review 5.  MPTP as a mitochondrial neurotoxic model of Parkinson's disease.

Authors:  Serge Przedborski; Kim Tieu; Celine Perier; Miquel Vila
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

6.  CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.

Authors:  Mikko Airavaara; Brandon K Harvey; Merja H Voutilainen; Hui Shen; Jenny Chou; Päivi Lindholm; Maria Lindahl; Raimo K Tuominen; Mart Saarma; Barry Hoffer; Yun Wang
Journal:  Cell Transplant       Date:  2011-09-22       Impact factor: 4.064

7.  Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease.

Authors:  Hiroshi Ichinose; Ken-Ichi Inoue; Shinobu Arakawa; Yuki Watanabe; Hiroki Kurosaki; Shoko Koshiba; Eldbjorg Hustad; Masahiko Takada; Jan O Aasly
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

8.  D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.

Authors:  Kim Tieu; Celine Perier; Casper Caspersen; Peter Teismann; Du-Chu Wu; Shi-Du Yan; Ali Naini; Miquel Vila; Vernice Jackson-Lewis; Ravichandran Ramasamy; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 9.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Authors:  Vivian P Chou; Novie Ko; Theodore R Holman; Amy B Manning-Boğ
Journal:  J Vis Exp       Date:  2014-01-07       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.